Pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the Unaudited Financial Results of the Company for ....

Pfizer Limited The Capital, 1802/1901, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel : +91 22 6693 2000 Fax : +91 22 2654 0274 July 28, 2026 The Corporate Relationship Dept. The Listing Dept. BSE Limited The National Stock Exchange of India Ltd. 1st Floor, P.J.Towers Exchange Plaza, 5th Floor, Plot No. C/1, Dalal Street, Fort G Block Bandra-Kurla Complex, Bandra (E) Mumbai – 400 001 Mumbai – 400 051 Scrip Code: 500680 Scrip Symbol: PFIZER Dear Sirs / Madam, Sub: Outcome of Board Meeting – Unaudited Financial Results for the quarter ended June 30, 2026. Ref.: Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the Unaudited Financial Results of the Company for the quarter ended June 30, 2026, which were approved by the Board of Directors of the Company at their Meeting held today i.e., July 28, 2026, that commenced at 11.30 a.m. and concluded at 1.35 p.m. Also please find enclosed herewith the Limited Review Report issued by the Statutory Auditors, B S R & Co. LLP, in respect of the said Unaudited Financial Results. Request you to please take the above on record. Thanking you, Yours truly, For Pfizer Limited Prajeet Nair Director – Corporate Services & Company Secretary Cc: National Securities Depository Limited (NSDL) Central Depository Services (India) Limited (CDSL) KFin Technologies Limited CIN: L24231MH1950PLC008311 Email ID: contactus.india@pfizer.com Website: www.pfizerltd.co.in 14th Floor, Central B Wing and North C Wing BS R & Co. LLP Nesco IT Park 4, Nesco Center Western Express Highway Chartered Accountants Goregaon (East). Mumbai - 400 063, India Telephone: +91 (22) 6257 1000 Fax: +91 (22) 6257 1010 Limited Review Report on unaudited financial results of Pfizer Limited for the quarter ended 30 June 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended To the Board of Directors of Pfizer Limited 1. We have reviewed the accompanying Statement of unaudited financial results of Pfizer Limited (hereinafter referred to as "the Company") for the quarter ended 30 June 2026 ("the Statement"). 2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting'' ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 241 O "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit. 5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations. including the manner in which ii is to be disclosed, or that it ~eg,stered Offtce: BS R & Co. (a partnership firm with Regi$trahon No. 8A61223) convened into BS R & Co. LLP (a 141h Floor, Central B Wing and Not1h C Wing. Neseo IT Patk ◄, Nesco Limited liability Partnership wilh LLP Registtalion No. AAS-8181) "Mth effect from October ·14, 2013 Center. Western Exp(ess Highway, Goteg.aGl"t (East}, Mumbai. 400063 Page 1 of 2 BS R & Co. LLP Limited Review Report (Continued) Pfizer Limited contains any material misstatement. For B S R & Co. LLP Chartered Accountants Firm's Registration No.:101248W/W-100022 Sreeja Marar Partner Mumbai Membership No.: 111410 28 July 2026 UDIN:26111410QWTGZG8008 Page 2 of2 Pfizer Limited The Capital, 1802/1901, Plot No. C -70, G Block. Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel: +91 22 6693 2000 Fax: +91 22 2654 0274 Statement of Unaudited Financial Results for the Quarter ended 30 June 2026 (~ in crore except earnings per share) 3 months ended 3 months ended Corresponding 3 Previous year 30/06/2026 31/03/2026 months ended in ended Particulars the previous year 31/03/2026 30/06/2025 Unaudited Audited Unaudited Audited (Refer note 4) 1 Income (a} Revenue from operations 653.17 629.23 603.05 2,519.65 (b) Other income 44.84 40.72 67.17 187.95 698.01 669.95 670.22 2,707.60 Total income 2 Expenses (a) Cost of materials consumed 105.02 83.04 88.69 309.51 (b) Purchases of stock-in-trade 182.89 117.69 124.28 608.39 (c) Changes in inventory of finished goods, work-in-progress and stock-in-trade (47.80) 19.63 (1.74) (33.59) (d) Employee benefits expense 82.08 77.18 95.82 367.97 (e) Finance costs 1.46 2.11 3.25 9.48 (f) Depreciation and amortization expense 14.26 14.78 14.41 57.73 (g} Other expenses 83.42 95.74 85.98 363.28 421.33 410.17 410.69 1,682.77 Total expenses 3 Profit before tax and exceptional items (1 -2) 276.68 259.78 259.53 1,024.83 4 Exceptional items (Refer Note 5) - 9.04 - {49.16) 5 Profit before tax (3 + 4) 276.68 268.82 259.53 975.67 6 Tax expense (a) Current tax 70.93 66.64 67.39 257.52 {b) Deferred tax 1.28 2.36 0.39 {4.28) 7 Net profit for the period/year (5 -6) 204.47 199.82 191.75 722.43 8 Other comprehensive income (a) Items that will not be reclassified subsequently to profit or loss (0.72) 5.05 (1.23) 5.11 {b) Income tax related to items that will not be reclassified to profit or loss 0.18 {1.25) 0.31 (1.27) Other comprehensive income, net of taxes (0.54) 3.80 (0.92) 3.84 9 Total comprehensive income for the period/ year (7 + 8) 203.93 203.62 190.83 726.27 10 Paid-up equity share capital (Face value per share HO) 45.75 45.75 45.75 45.75 4,157.15 11 Other equity 12 Earnings per share -Basic and Diluted (of no/-each) II • * • Computed on the basis of net profit for the period/year 44.69 43.68 41.91 157.92 II Earnings per share -Basic and Diluted before Exceptional items 44.69 42.21 41.91 165.88 *Not annualised CIN: L24231MH19S0PLC008311 Email ID: ntactus ind1c1@pf1zer com Website: www pf,zerltd co an NOTES: 1. The above financial results were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on July 28, 2026. 2. The financial results of the Company have been prepared in accordance with Indian Accounting Standards ('Ind AS") prescribed under Section 133 of the Companies Act, 2013 [Showing first 8,000 characters — download PDF for full document]